Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
SYSTEMATIC REVIEW/META-ANALYSIS
GLP-1 receptor agonists and tendon healing: a systematic review and meta-analysis
1
College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
2
Department of Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
Submission date: 2026-03-15
Final revision date: 2026-06-25
Acceptance date: 2026-06-29
Online publication date: 2026-08-20
Corresponding author
Yasir M. Khayyat
Department of Medicine Faculty of Medicine Umm Al-Qura University Al-Awali District Makkah, 8156-24381 Saudi Arabia Phone: +966125270000, ext: 4020-4084
Department of Medicine Faculty of Medicine Umm Al-Qura University Al-Awali District Makkah, 8156-24381 Saudi Arabia Phone: +966125270000, ext: 4020-4084
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are prescribed for cardiometabolic indications and may exert anti-inflammatory and tissue-regenerative effects. However, their effect on tendon healing and tendon-related surgical outcomes remains unclear. In this systematic review and meta-analysis, we evaluated the available preclinical and clinical evidence on the effects of GLP-1RAs on tendon healing and related musculoskeletal outcomes.
Methods:
A systematic search of the PubMed, Embase, Medline, Scopus, Clinical Key, Google Scholar, and Cochrane databases was conducted from database inception to December 31, 2025. Eligible studies included animal studies, human experimental studies, and retrospective clinical cohorts that evaluated GLP-1RA exposure in relation to tendon biology, tendon healing, or tendon-related orthopedic outcomes. Risk of bias was assessed using design-appropriate tools, including SYRCLE, ROBINS-I, the Newcastle-Ottawa Scale, SANRA, AMSTAR 2, and the NIH assessment tool.
Results:
A total of 41 studies were included: eight animal studies, three human experimental studies, six retrospective cohort studies, one prospective study, 18 review or commentary articles, and five systematic reviews. Preclinical evidence generally supported the tendon-promoting effects of GLP-1RAs through the modulation of inflammation, fibroblast activity, angiogenesis, and extracellular matrix remodeling. Quantitative synthesis of two retrospective cohorts evaluating revision risk after total shoulder arthroplasty suggested a lower risk among GLP-1RA users than non-users. However, only two studies were eligible for pooling, and significant clinical heterogeneity remained across the available cohorts.
Conclusions:
GLP-1RAs demonstrate biologically plausible tendon healing benefits in preclinical models, with a potentially favorable association with selected postoperative outcomes; however, causal inference remains limited by retrospective design, heterogeneity, and potential confounding factors.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are prescribed for cardiometabolic indications and may exert anti-inflammatory and tissue-regenerative effects. However, their effect on tendon healing and tendon-related surgical outcomes remains unclear. In this systematic review and meta-analysis, we evaluated the available preclinical and clinical evidence on the effects of GLP-1RAs on tendon healing and related musculoskeletal outcomes.
Methods:
A systematic search of the PubMed, Embase, Medline, Scopus, Clinical Key, Google Scholar, and Cochrane databases was conducted from database inception to December 31, 2025. Eligible studies included animal studies, human experimental studies, and retrospective clinical cohorts that evaluated GLP-1RA exposure in relation to tendon biology, tendon healing, or tendon-related orthopedic outcomes. Risk of bias was assessed using design-appropriate tools, including SYRCLE, ROBINS-I, the Newcastle-Ottawa Scale, SANRA, AMSTAR 2, and the NIH assessment tool.
Results:
A total of 41 studies were included: eight animal studies, three human experimental studies, six retrospective cohort studies, one prospective study, 18 review or commentary articles, and five systematic reviews. Preclinical evidence generally supported the tendon-promoting effects of GLP-1RAs through the modulation of inflammation, fibroblast activity, angiogenesis, and extracellular matrix remodeling. Quantitative synthesis of two retrospective cohorts evaluating revision risk after total shoulder arthroplasty suggested a lower risk among GLP-1RA users than non-users. However, only two studies were eligible for pooling, and significant clinical heterogeneity remained across the available cohorts.
Conclusions:
GLP-1RAs demonstrate biologically plausible tendon healing benefits in preclinical models, with a potentially favorable association with selected postoperative outcomes; however, causal inference remains limited by retrospective design, heterogeneity, and potential confounding factors.
REFERENCES (44)
1.
Bacci S, Laurino A, Manni ME, et al. The pro-healing effect of exendin-4 on wounds produced by abrasion in normoglycemic mice. Eur J Pharmacol 2015; 764: 346-52.
2.
Bhosale AG, Hashilkar NK, Patil SY. Evaluation of dulaglutide in acute and subacute inflammation models of male wistar rats: an experimental study. J Clin Diagn Res 2025; 19: FC11-6.
3.
Lotti V, De Siena G, Bacci S. Effects of exendin-4 on diabetic wounds: firect action on proliferative phase of wound healing. Biocell 2024; 48: 1751-9.
4.
Paroli G, Murciano N, Mancini C, et al. The role of mast cells in cellular modifications evoked by exendin-4 in treated wounds: a preclinical study. J Wound Care 2022; 31: 701-8.
5.
Que Q, Guo X, Zhan L, et al. The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis. J Inflamm 2019; 16: 13.
6.
Yoon JP, Park SJ, Kim DH, et al. GLP-1RA reduces supraspinatus fatty infiltration and promotes functional recovery in a rat model of rotator cuff repair. Am J Sports Med 2025; 53: 2973-83.
7.
Bozadjieva-Kramer N, McMahon G, Li Z, et al. Gut-derived FGF15 modulates lean mass, bone, and bile acid responses to weight loss. Diabetes 2026; 75: 938-50.
8.
Xiang J, Qin L, Zhong J, Xia N, Liang Y. GLP-1RA liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway. Diabetes Metab Syndr Obes 2023; 16: 2433-46.
9.
Abdulmalik S, Ramos D, Rudraiah S, Banasavadi-Siddegowda YK, Kumbar SG. The glucagon-like peptide 1 receptor agonist exendin-4 induces tenogenesis in human mesenchymal stem cells. Differentiation 2021; 120: 1-9.
10.
Lynskey SJ, Ling Z, Ziemann M, Gill SD, McGee SL, Page RS. Loosening the lid on shoulder osteoarthritis: how the transcriptome and metabolic syndrome correlate with end-stage disease. Int J Mol Sci 2025; 26: 3145.
11.
Tsilingiris D, Natsi AM, Gavriilidis E, et al. Interleukin-8/matrix metalloproteinase-9 axis impairs wound healing in type 2 diabetes through neutrophil extracellular traps-fibroblast crosstalk. Eur J Immunol 2025; 55: e202451664.
12.
Lawand JJ, Tansey PJ, Ghali A, et al. Glucagon-like peptide-1 receptor agonist use is associated with increased risk of perioperative complication and readmission following shoulder arthroplasty. J Shoulder Elbow Surg 2025; 34: 1152-7.
13.
Megerian MF, Reddy RP, Kim BI, et al. Glucagon-like peptide-1 receptor agonist use is not associated with reduced postoperative complications in obese patients after total shoulder arthroplasty. Semin Arthroplasty JSES 2025; 35: 591-8.
14.
Omurzakov A, Omurzakov AM, Reddy RP, et al. Perioperative glucagon-like peptide-1 receptor agonist use is not associated with increased complications in obese patients undergoing total shoulder arthroplasty: a propensity-matched large database study. Semin Arthroplasty JSES 2025; 35: 604-11.
15.
Rasmussen ST, Ilyas AM. Glucagon-like peptide-1 receptor agonist use is not associated with increased reoperation risk following rotator cuff repair. J Orthop 2025; 70: 235-40.
16.
Seddio AE, Moran J, Gouzoulis MJ, et al. Lower risk of postoperative complications and rotator cuff retear associated with semaglutide use in patients with type II diabetes mellitus undergoing arthroscopic rotator cuff repair. Arthroscopy 2025; 41: 199-206.
17.
Su YC, Hsieh PC, Lai ECC, Lin YC. Risk of rotator cuff tear and rotator cuff repair surgery comparison between sodium-glucose cotransporter 2 inhibitors and glucagon like peptide-1 receptor agonists: a real-world study. Diabetes Metabolism 2024; 50: 101522.
18.
Abraham AC, Shah SA, Thomopoulos S. Targeting inflammation in rotator cuff tendon degeneration and repair. Tech Shoulder Elb Surg 2017; 18: 84-90.
19.
Ali A, Flatt PR, Irwin N. Gut-derived peptide hormone analogues and potential treatment of bone disorders in obesity and diabetes mellitus. Clin Med Insights Endocrinol Diabetes 2024; 17: 11795514241238059.
20.
Arora M, Bhadada SK. Diabetes and rotator cuff repair: a narrative review. J Arthrosc Joint Surg 2020; 7: 167-71.
21.
Gatto A, Liu K, Milan N, Wong S. The effects of GLP-1 agonists on musculoskeletal health and orthopedic care. Curr Rev Musculoskel Med 2025; 18: 469-80.
22.
Magruder ML, Jacofsky D, Springer B, Scuderi GR, Hameed D, Mont MA. Semaglutide and other GLP-1 agonists: a Boon for the arthroplasty industry? J Arthroplasty 2024; 39: 277-82.
23.
Mashayekhi Y, Asgari AM, Pahlevan-Fallahy MT, Karimi MA, Jalali R, Shaker F. Impact of glucagon-like peptide-1 receptor agonists on postoperative complications after total joint arthroplasty: a systematic review and meta-analysis. J Orthop Surg 2025; 33: 10225536251391959.
24.
Mulcahy J, DeLaRosby A, Norwood T. Transforming care: implications of glucagon like peptide-1 receptor agonists on physical therapist practice. Phys Ther 2025; 105: pzaf061.
25.
Muskiet MHA, Winter EM, Rensen PCN, Appelman-Dijkstra NM, de Jongh RT. The gut–bone axis: implications of gut hormone-based therapies for bone health. Lancet Diabetes Endocrinol 2025; 13: 364-7.
26.
Nowicki JK, Jakubowska-Pietkiewicz E. Osteocalcin: beyond bones. Endocrinol Metabol 2024; 39: 399-406.
27.
Takashi Y, Kawanami D. The role of bone-derived hormones in glucose metabolism, diabetic kidney disease, and cardiovascular disorders. Int J Mol Sci 2022; 23: 2376.
28.
Weber L, Hashemnia Sharbabaki M, Fuchs B, et al. The influence of GLP-1 agonists on human mesenchymal stem cells: a systematic review. Stem Cell Rev Rep 2026; 22: 26-46.
29.
Yang Q, Fu B, Luo D, et al. The multiple biological functions of dipeptidyl peptidase-4 in bone metabolism. Front Endocrinol 2022; 13: 856954.
30.
Zhang KW, Liu SY, Jia Y, et al. Insight into the role of DPP-4 in fibrotic wound healing. Biomed Pharmacother 2022; 151: 113143.
31.
Zheng M, Zhao J, Wang Y, et al. Exploring new therapeutic drugs for osteoarthritis and osteoporosis: glucagon-like peptide-1 receptor agonists: a review. Medicine 2025; 104: e43239.
32.
Srivastava G, Apovian C. Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon. Curr Obes Rep 2018; 7: 147-61.
33.
Jódar E. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy]. Med Clin 2014; 143 Suppl 2: 12-7.
34.
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
35.
González-Luis A, Llinares-Arvelo V, Martínez-Alberto CE, et al. Glucagon-like peptide-1 receptor agonists and muscle health: potential role in sarcopenia prevention and treatment. Eur J Endocrinol 2025; 193: R31-44.
36.
Bujdei-Tebeica I, Mihai DA, Pantea-Stoian AM, Stefan SD, Stoicescu C, Serafinceanu C. Effects of blood-glucose lowering therapies on body composition and muscle outcomes in type 2 diabetes: a narrative review. Medicina 2025; 61: 1399.
37.
Scheen AJ. GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies. Diabetes Metab 2025; 51: 101681.
38.
Maihemuti A, Cui C, Wang Q, et al. Glucagon like peptide-1 receptor agonists for sarcopenia and muscle wasting disorders: a systematic review of efficacy and mechanisms. Aging Dis 2025. doi: 10.14336/AD.2025.1165.
39.
Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab 2024; 26 Suppl 4: 16-27.
40.
Ceasovschih A, Asaftei A, Lupo MG, et al. Glucagon-like peptide-1 receptor agonists and muscle mass effects. Pharmacol Res 2025; 220: 107927.
41.
Cannavaro D, Leva F, Caturano A, Berra CC, Bonfrate L, Conte C. Optimizing body composition during weight loss: the role of amino acid supplementation. Nutrients 2025; 17: 2000.
42.
Prokopidis K, Daly RM, Suetta C. Weighing the risk of GLP-1 treatment in older adults: should we be concerned about sarcopenic obesity? J Nutr Health Aging 2025; 29: 100652.
43.
Pantazopoulos D, Gouveri E, Papazoglou D, Papanas N. GLP-1 receptor agonists and sarcopenia: weight loss at a cost? A brief narrative review. Diabetes Res Clin Pract 2025; 229: 112924.
44.
Alissou M, Demangeat T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study. Diabetes Obes Metab 2026; 28: 112-21.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
